Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Ifupinostat shows activity in relapsed DLBCL in phase 2 study

Ifupinostat produced responses in heavily pretreated relapsed or refractory DLBCL, with thrombocytopenia the leading safety concern in phase 2 testing.

By Dr. Revathy Mohan V.R., MBBS · Oct 20, 2026 · 4 min read

Oncology·JCO

Disitamab Vedotin, Tislelizumab, and S-1 Tested in HER2-Positive Gastric Cancer

Phase II trial tested first-line disitamab vedotin, tislelizumab, and S-1 in HER2-overexpressing advanced gastric or GEJ adenocarcinoma.

Oct 20, 2026

Oncology·JCO

Patient-Reported Outcomes Track Cancer Care Costs and Resource Use

Ontario cohort data link higher symptom burden to less cancer-directed treatment and more ancillary care, supporting patient-centered value…

Oct 20, 2026

Oncology·JCO

Outpatient Medical Oncology Visits Rose Sharply in Ontario Cohort

Ontario registry data show rising outpatient medical oncology use from 2015 to 2022, with large increases in consultations,…

Oct 20, 2026

Oncology·JCO

Ewing Sarcoma Outcomes in Euro-EWING99 Define Prognostic Drivers

Euro-EWING99 followed 3,395 patients with Ewing sarcoma and confirmed survival patterns, risk-group differences, and the prognostic value of…

Oct 20, 2026

Oncology·JCO

ASCO Living Guideline on Multiple Myeloma Sets a Continuous Update Model

ASCO’s 2026 living guideline for multiple myeloma emphasizes continuous evidence review, regular updates, and clinician judgment in rapidly…

Oct 20, 2026

Oncology·Nature

University of Oklahoma Opens Open-Rank Oncology Faculty Search

The University of Oklahoma Health Sciences Center is recruiting open-rank oncology faculty with cancer metabolism, signaling, and immunology…

Oct 20, 2026

Oncology·MHRA

Personalized breast cancer screening meets resistance in lower-risk women

Healthcare professionals in MyPeBS saw low-risk results as reassuring, but raised concerns about screening interval reduction, equity, and…

Oct 20, 2026

Oncology·CMAJ

Early Death Risk in De Novo Metastatic Breast Cancer Tied to Marginalization

Ontario data link early death in de novo metastatic breast cancer to marginalization, primary care access, and rural…

Oct 20, 2026

Oncology·Nature

Entinostat and Exemestane Extend Survival in Advanced Breast Cancer

Long-term follow-up from EOC103A3101 links entinostat plus exemestane with longer survival and more chemotherapy-free time in HR-positive advanced…

Oct 20, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.